Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Short-term and long-term efficacies of combined use of irbesartan and calcitriol for the treatment of IgA nephropathy

Laming Li¹, Yan Jiang²

¹Department of Nephrology, The Second People's Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University, Hefei 230011, Anhui Province, China; ²Department of Nephrology, Lin'an District People's Hospital, Hangzhou 311300, Zhejiang Province, China.

For correspondence:- Yan Jiang Email: xiaoxiaotang789@163.com

Accepted: 26 August 2023 Published: 30 September 2023

Citation: Li L, Jiang Y. Short-term and long-term efficacies of combined use of irbesartan and calcitriol for the treatment of IgA nephropathy. Trop J Pharm Res 2023; 22(9):1907-1913 doi: 10.4314/tjpr.v22i9.19

© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To determine the efficacy and safety of irbesartan plus calcitriol in the treatment of IgA nephropathy, and its effect on inflammatory injury and complement system

Methods: Differences in renal function, inflammatory response, immune function, complement factor levels, clinical efficacy, and incidence of adverse reactions between IgA nephropathy patients treated with irbesartan (control, n = 50) and those treated with irbesartan + calcitriol (study group, n = 50) after 2 and 12 months, were retrospectively analyzed. As treatment progressed, protein in 24-h urine, and creatinine and BUN in both groups were gradually reduced.

Results: The serum levels of complement factors C1q and C3 in both groups gradually increased, while C4 level gradually decreased. Relative to pre-treatment, at 2- and 12-months post-treatment, serum levels of C1q and C3 in both groups were raised, while C4 level decreased (p < 0.05). Relative to control, serum C1q and C3 in the study group were raised, while C4 level was decreased (p < 0.05). Relative to the control group, total treatment effectiveness in the study group increased at 2- and 12-months post-treatment (p < 0.05). There was no significant difference in the incidence of adverse reactions between the control and study groups during the treatment.

Conclusion: Treatment with irbesartan + calcitriol significantly improves renal function in patients with IgA nephropathy, reduces inflammatory response, and improves immune function and clinical effectiveness with high safety profile. More clinical trials should be carried out to validate the findings of this study.

Keywords: Irbesartan, Calcitriol, IgA nephropathy, Renal function, Inflammatory response, Immune function